Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Chordia Therapeutics Inc. ( (JP:190A) ) has shared an announcement.
Chordia Therapeutics reported non-consolidated results for the quarter ended 30 November 2025 showing no business revenue and a narrowed operating loss of ¥306 million, improving from a ¥624 million loss a year earlier, with quarterly net loss per share reduced to ¥4.24 from ¥9.07. Total assets declined to ¥2.48 billion and equity decreased slightly, but the company maintained a strong equity ratio of 92.1%, continued its no-dividend policy for the current and forecast fiscal year, and projected a full-year net loss of ¥1.96 billion, underscoring its ongoing investment phase and the likelihood of continued losses in the near term for shareholders.
The most recent analyst rating on (JP:190A) stock is a Hold with a Yen105.00 price target. To see the full list of analyst forecasts on Chordia Therapeutics Inc. stock, see the JP:190A Stock Forecast page.
More about Chordia Therapeutics Inc.
Chordia Therapeutics Inc. is a Japan-based biopharmaceutical company listed on the Tokyo Stock Exchange, focused on the discovery and development of therapeutic drugs. Operating under Japanese GAAP, it remains in a development-intensive phase with no recorded business revenue and relies on equity financing, as reflected in its high equity ratio and absence of dividend payments.
Average Trading Volume: 861,330
Technical Sentiment Signal: Sell
Current Market Cap: Yen8.37B
For a thorough assessment of 190A stock, go to TipRanks’ Stock Analysis page.